OTTAWA, ON / ACCESSWIRE / March 23, 2017 / Panda Capital Inc. (TSX-V: PDA.H) (the “Company” or the “Resulting Issuer”) is pleased to provide an update with respect to the proposed amalgamation (the “Transaction”) between ABcann Medicinals Inc. (“ABcann”), the Company and a wholly-owned subsidiary of the Company formed for the purposes of completion of the amalgamation, which will result in the reverse takeover of the Company by ABcann and will constitute the Company’s Qualifying Transaction (as defined in the policies of the TSX Venture Exchange (the “TSXV”)), as initially announced by news release dated December 2, 2016. The Company and ABcann continue to work towards completion of the Transaction. Initial submissions, including submission of a draft filing statement with respect to the Transaction (the “Filing Statement”), have been made to the TSXV and are currently under review.

The Company is also pleased to announce that, in connection with the Transaction, it intends to undertake two concurrent financings:

a non-brokered private placement of secured convertible debentures (the “Debentures”) in the aggregate principal amount of $15 million (the “Debenture Financing”) with two industry leading institutions, having a conversion price equal to a 30% premium to the price ascribed to the Subscription Receipts issued pursuant to the Subscription Receipt Financing (each as defined below), subject to adjustment; and

a brokered private placement of subscription receipts (each, a “Subscription Receipt”) at a price of $0.80 per Subscription Receipt (the “Issue Price”) for gross proceeds of $8,000,000 (the “Subscription
Receipt Financing” and, together with the Debenture Financing, the “Concurrent Financings”).

Additional details with respect to the Concurrent Financings are provided below.

“We look forward to closing the Qualifying Transaction and the Concurrent Financings, following which the Company will commence an immediate expansion of ABcann’s existing Vanluven facility to double production capacity and break ground at the new 150,000 square foot purpose built Kimmett facility,” stated Aaron Keay, a director of the Company. “The closing of the Qualifying Transaction is a significant step forward for the Company, and will provide us the growth capital to expand ABcann’s footprint in Canada and take advantage of potential international opportunities.”

Ken Clement, founder of ABcann, commented, “We are very excited about bringing ABcann public and the opportunities it offers to both increase the scale and capacity of our facilities and to provide increased liquidity for our shareholders. We look forward to working with Aaron Keay, in his new role as CEO following the closing, as ABcann progresses to this next step in its expansion and development.”

Concurrent Financings

Debenture Financing

In connection with, and subject to, the closing of the Transaction, it is also expected that the Debenture Financing will be completed, pursuant to which the Resulting Issuer is expected to issue Debentures in the aggregate principal amount of $15,000,000.

The Debentures will:

bear interest at the rate of 10% per annum, commencing on the issue date of the Debentures, and payable semi-annually on the last day of June and December of each year;

mature 36 months following the closing of the Debenture Financing and be secured by a security interest over all of the assets of the Resulting Issuer and each of its subsidiaries. Any outstanding indebtedness of the Resulting Issuer (other than existing debentures of ABcann in the aggregate principal amount of $5,000,000 held by the lead subscribers in the Debenture Financing) shall be subordinated to the Debentures as of the closing of the Debenture Financing; and

be convertible at the option of the holder into common shares of the Resulting Issuer (each, a “Share”) at any time prior to the close of business on the maturity date at a conversion price (the “Conversion Price”) equal to an amount which represents a 30% premium to the Issue Price per Subscription Receipt. Given that the Issue Price per Subscription Receipt is expected to be $0.80, it is expected that the Conversion Price will be $1.04 per Share. In the event that the Resulting Issuer completes a subsequent equity financing at a price below the Conversion Price, the Conversion Price will be adjusted downward to the price per share of any subsequent equity financing, subject to a floor price equal to the Issue Price per Subscription Receipt; and

if at any time prior to the maturity date, the volume weighted average price of the Shares on the TSXV (or such other stock exchange or quotation system as the Shares are then principally listed or quoted) for any consecutive 10 day trading period is greater than $1.80, the Company, at its sole option, may, at any time thereafter, force a conversion of the Debentures.

At the closing of the Debenture Financing, the Resulting Issuer will also issue certain warrants to the holders of the Debentures, which will vest and become exercisable on July 1, 2018 if the Resulting Issuer has not completed, on or before that date, one or more financings for aggregate proceeds of at least $18 million through: (i) the exercise of outstanding warrants or a new equity issuance from treasury (or a combination of both); (ii) a debt facility acceptable to the lead subscribers in the Debenture Financing, or (iii) a combination of both. Additional details regarding the terms of these warrants and the Debentures, including certain adjustment and acceleration provisions in connection therewith, will be included in the Filing Statement.

Subscription Receipt Financing

The Company and ABcann have entered into an engagement letter with Canaccord Genuity Corp. (“Canaccord Genuity”) and PI Financial Corp. (“PI Financial”) pursuant to which Canaccord Genuity and PI Financial (together, the “Agents”) have agreed to act as co-lead agents in respect of the Subscription Receipt Financing, under which the Company is expected to issue an aggregate of 10,000,000 Subscription Receipts at a price of $0.80 per Subscription Receipt (the “Issue Price”) for gross proceeds of $8,000,000. Each Subscription Receipt shall be deemed to be exercised immediately prior to the completion of the Transaction, without payment of any additional consideration and without further action on the part of the holder thereof, into one Share. The Agents will also be granted an over-allotment option to acquire such number of additional Subscription Receipts as is equal to 15% of the Subscription Receipts sold under the Subscription Receipt Financing. The additional Subscription Receipts will have the same terms as the Subscription Receipts. The over-allotment option will be exercisable until closing of the Subscription Receipt Financing (the “Subscription Receipt Closing”).

Upon the Subscription Receipt Closing, the gross proceeds of the Subscription Receipt Financing will be held by an escrow agent acceptable to the Company, ABcann and the Agents. If the Agents have not received a notice from the Company and ABcann that all the conditions precedent to the release of the escrowed proceeds have been satisfied or waived to the satisfaction of the Company, ABcann and the Agents by 5:00 p.m. (Vancouver time) on the date that is 60 days following the Subscription Receipt Closing (or such other date as may be determined by the Company, ABcann and the Agents), all of the Subscription Receipts will be cancelled by the escrow agent and holders thereof will have no rights thereunder except to receive, and the escrow agent shall pay to such holders from the escrowed funds, an amount equal to the aggregate purchase price of the Subscription Receipts then held.

The Company has agreed to: (i) pay the Agents a commission equal to 7% of the gross proceeds raised from subscribers identified by the Agents, and 3.5% of the gross proceeds raised from subscribers identified by the Company and ABcann (who will be permitted to subscribe for up to 20% of the Subscription Receipt Financing), and (ii) issue the Agents compensation options to acquire such number of Shares as is equal to 7% of the Subscription Receipts issued to subscribers identified by the Agents and 3.5% of the Subscription Receipts issued to subscribers identified by the Company and ABcann. Each of the compensation options will be exercisable to acquire one Share at the Issue Price for a period of two years following the Subscription Receipt Closing. The Agents will also be reimbursed for their reasonable expenses in connection with the Subscription Receipt Financing.

Completion of the Concurrent Financings will be subject to various conditions, including receipt of the approval of the TSXV, the approval of the boards of directors of the Company and ABcann, and other conditions as will be set out in the definitive agreements with respect to the Concurrent Financings. The proceeds of the Concurrent Financings will be primarily be used for expansion of the existing ABcann Vanluven facility, development and construction of the proposed ABcann Kimmett facility, research and development, negotiation of international licensing and distribution agreements, and general working capital purposes.

Any securities issued in connection with the Concurrent Financings (including, for greater certainty, the Shares), will be subject to a statutory hold period of four months and one day from the applicable Concurrent Financing closing date.

Proposed Directors and Officers of Resulting Issuer

As will be further described in the Filing Statement, the following individuals have been identified as proposed directors and officers of the Company following completion of the Transaction:

Ken Clement – Napanee, Ontario – Executive Chairman and Director

Mr. Clement is the founder of ABcann and has served as its general manager since June 2012. He began investigation into the potential for medical marijuana in 2009 and has been the driving force behind ABcann’s development.

Aaron Keay – Vancouver, British Columbia – CEO
and Director

Mr. Keay has been a director of the Company since November 2015. He has spent more than a decade working in the capital markets across a broad spectrum of sectors, including life sciences, food and beverages, and natural resources, in varied roles, including corporate finance, senior management and as a director of a number of public companies. He has helped many companies move from the private to the public markets.

Paul Lucas – Oakville, Ontario – Director

Mr. Lucas is a director of ABcann. He served as President and CEO of GlaxoSmithKline Canada from 1994 until he retired in 2012. He also served as Chairman of the Board of Directors for TM Bioscience, and as a director of Biochem Pharma, the Toronto Regional Research Alliance, Montreal inVivo, and AllerGen. In addition, he was a member of the Principal’s Advisory Council of the University of Toronto at Mississauga, and a member of the Board of Trustees of Queen’s University. He also served as Chairman of the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D) for three terms. Currently, Mr. Lucas is a member of the Board of Directors of RnA Diagnostics Inc. and the Ontario Genomics Institute. He is also Chair of the Board of EcoSynthetix Inc., Induran Ventures Inc. and Life Sciences Ontario. He received his BSc (Honours) in Biology and Chemistry from Queen’s University in 1972, and obtained his Chartered Directors designation (CDir) from the Directors College, a joint venture of McMaster University and the Conference Board of Canada, in 2009.

John Easson – Oakville, Ontario – Director

Mr. Easson has over 23 years of experience advising companies with respect to corporate finance matters and mergers and acquisitions. Prior to founding BE Capital Advisors in 2008, he was Managing Director, Head of Media, Communications & Technology Group, Investment & Corporate Banking, at BMO Capital Markets. Mr. Easson joined BMO in April of 2001, having spent the previous five years focusing on Communications & Technology investment banking at RBC Dominion Securities. He has been involved in a variety of financial advisory and corporate finance transactions for a wide range of clients, including RIM, Macdonald Dettwiler, Clearnet, Evertz and Sierra Wireless. He also acted as an M&A advisor to numerous companies, including Rogers, BCE, Clearnet, Filogix and FMC. More recently, through BE Capital Advisors, Mr. Easson has worked with smaller cap companies, delivering expertise to drive successful corporate transactions in a variety of industries, including insurance, distribution, event marketing, logistics, mortgage finance, technology services and healthcare. Mr. Easson obtained an MBA from the University of Toronto in 1994 and a B.Sc in Mechanical Engineering from Queen’s University in 1989.

Daryl Kramp – Madoc, Ontario – Director

Mr. Kramp was the Member of Parliament for the riding of Prince Edward-Hastings from 2004 to October 2015. While an MP, Mr. Kramp was honoured to be appointed by the Prime Minister as Chair of the Standing Committee on Public Safety and National Security (SECU). He also served on the Finance Committee and the Treasury Board Advisory Caucus, and acted as Vice-Chair of the Steering Committees and Standing Committees of Public Accounts and Government Operations and Estimates. Mr. Kramp has been elected as Co-Chair of the Canada-China Legislative Association and was a Member of the Executive of the Canada-Ireland Friendship Group and the Canada-Australia/New Zealand Group. Mr. Kramp was an active member of the Parliamentary Associations of the Commonwealth, NATO, and ParlAmericas, Canada-Europe, including the Inter-Parliamentary Associations of Canada-France, Canada-Japan, Canada-United Kingdom and Canada-United States, and the Inter-Parliamentary Union. In addition, Mr. Kramp was elected by his peers as the Canadian President of the Global Organization of Parliamentarians Against Corruption (GOPAC). He recently completed his studies at the Institute of Corporate Directors (Teflor School of Management). In addition to his political appointments, Mr. Kramp has created and operated several successful business ventures in the fields of retail, wholesale and hospitality. He also has experience as a trade consultant and as a sports promoter, having organized some of the largest international junior ice hockey tours in North America.

Andrew LaCroix – Duncan, British Columbia – Director and Vice-President of Business Development

Mr. LaCroix has been the principal of A. LaCroix Law Corp. since 2008. He oversaw ABcann’s initial successful Health Canada application to obtain its production license, and has provided general counsel to ABcann since inception. Mr. LaCroix obtained a Bachelor of Arts degree from the University of British Columbia in 1991 and a Bachelor of Laws from the University of Saskatchewan in 2001. He has been a member of the Law Society of British Columbia since 2002.

Neil Kapp – London, Ontario – Chief Operating
Officer

Mr. Kapp has been the Vice-President of Business Development of ABcann since August 2014. He has also worked as a self-employed business consultant, through his company, Pent-Land Holdings Inc., since January 1989. Mr. Kapp obtained a Bachelor of Business Administration, Honours, from York University in 1978.

Ying (Jenny) Guan – Napanee, Ontario – CFO
and Secretary

Ms. Guan joined ABcann in January 2013 and has held a variety of progressively more senior roles, most recently being appointed as CFO in January 2015. As a member of ABcann’s executive management team, she is responsible for corporate financial reporting, operations, treasury, tax, budget planning, corporate policies, internal controls and ABcann’s relationship with external auditors. Ms. Guan has over 15 years of experience in various key leadership roles in business operations, finance, and program management. She ran her family business from early 2000 until its sale in 2015.

Business of the Resulting Issuer

ABcann, a company incorporated under the laws of the Province of Ontario, was one of the first companies to obtain a production license under the Marihuana for Medical Purposes Regulations (Canada), which it received on March 21, 2014. It also obtained a sales license on December 31, 2015. Situated in Napanee, Ontario, ABcann has spent the last two years focused on changing the face of medical cannabis. ABcann’s current GPP (Good Production Practice) manufacturing Vanluven facility contains proprietary plant growing technology, combining the concepts, systems and components to produce industry leading, high yielding plants, which, in turn, generate high quality products that are consistent from batch to batch.

ABcann grows its plants without the use of chemicals and pesticides in controlled environmental chambers, where its technology allows it to optimize every key variable in the growing process to achieve the consistency that is needed for a standardized product. ABcann is able to control environmental and nutrient demands, tailor made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures, giving ABcann the ability to produce pharmaceutical grade, plant-based medicine that can be prescribed with confidence.

The following table sets out selected financial information of ABcann as at and for the periods indicated:

9 months ended

September 30, 2016

($)

(unaudited)

Year ended
December 31, 2015

($)

(audited)

Year ended
December 31, 2014

($)

(audited)

Revenue

210,750

–

–

Other income

128,175

73,680

853

Net loss

2,962,828

4,401,748

3,975,940

Net loss per share

0.05

0.07

0.09

Total assets

7,504,765

7,416,677

1,364,772

Long-term liabilities

1,512,970

–

350,000

Dividends per share

–

–

–

ABcann has invested $20.8 million in its current operations and international expansion plans, which include:

the developed and skillfully managed 14,500 square foot Vanluven facility in Napanee, where ABcann currently carries out its primary activities;

the acquisition of approximately 66 acres on four adjoining parcels of land (all of which are wholly-owned, directly or indirectly, by ABcann); and

the plan to commence construction for Phase 1 development of a new 952,000 square foot facility on these new properties, being the Kimmett facility, with the initial buildout comprising approximately 150,000 square feet.

Since the initial announcement of the Transaction on December 2, 2016, ABcann has settled approximately $1,600,000 dollars of outstanding debt by way of the issuance of units and common shares of ABcann, such that there are expected to be approximately 78.6 million ABcann shares outstanding which will be exchanged for Shares on a one for one basis at the closing of the Transaction. The Company also completed the issuance of debentures in the principal amount of $600,000. As a result of the foregoing, it is expected that the Resulting Issuer will have working capital of approximately $24,000,000 following completion of the Transaction, assuming completion of both of the Concurrent Financings.

The current directors of ABcann are John Molloy, Ying (Jenny) Guan, Timothy Humberstone, Dennis Chadwick and Paul Lucas, all of whom are residents of Ontario. Mr. Molloy and Ms. Guan are also officers of ABcann. The controlling shareholder of ABcann is the Linda Smith Family Trust, a trust formed under the laws of the Province of Ontario, the trustee of which is Ken Clement, also a resident of Ontario.

Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed on the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.

ON BEHALF OF THE BOARD OF DIRECTORS OF PANDA CAPITAL INC.

“Aaron Keay”

Aaron Keay

Director

For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@informcapital.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

PANDA CAPITAL INC.
Suite 2600 – 160 Elgin Street
Ottawa, Ontario K1P 1C3

SOURCE: Panda Capital Inc.

ReleaseID: 458067

MESQUITE, NV / ACCESSWIRE / March 23, 2017 / CANNABIS SATIVA, INC. (OTCQB: CBDS) is pleased to announce that its subsidiary iBudtender will unveil its new APP this weekend at the HempCon, “Heart of Nature Fest”, taking place at the Sonoma County Fairgrounds in Santa Rosa, California this Friday: 3PM–9PM, Saturday: 11AM–9PM & Sunday: 11AM-7PM.

Attendees are invited to stop at the iBudtender booth to check out the new APP which “We believe contains the highest standards in product safety for cannabis patients of any existing app”, said Cannabis Sativa President David Tobias.

Ibudtender APP features patient reviews, nutritional information, directions, warnings, local availability and more. Find a product based on your preferences, needs, symptoms or conditions, then order it locally for pickup or delivery.

Business owners are encouraged to visit the iBudtender booth and sign up to preview the iBudtender business platform for Dispensaries, Delivery Services and Manufacturers, for a no obligation 30 day trial period. The B2B platform is designed to increase business as well as promote data sharing in an effort to help patients find the best and most effective products.

Heart of Nature is a medical marijuana show catering to those who may benefit from the medical use of marijuana. Medical marijuana dispensaries, collectives, caregivers, evaluation services, legal services, educational institutions, equipment, accessories, and live entertainment. Heart of Nature’s educational events include seminars and presentations by industry leaders, advocates, and attorneys. HempCon is a Prop 215 Friendly Event.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company’s success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact Information:

Investor Relations
Mesquite, NV 89027
702-345-4074
http://www.cannabissativainc.com

SOURCE: Cannabis Sativa Inc.

ReleaseID: 458066

CALGARY, AB / ACCESSWIRE / March 23, 2017 / QuikFlo Health Inc. (“QuikFlo” or the “Company”) (TSX-V: QF)(FSE: 1QF) announces that it has closed the first closing of its previously announced non-brokered private placement. The Company issued 64,314,444 units at a price of $0.075 per unit, with each unit consisting of one common share and one half of a share purchase warrant entitling the holder to purchase one additional common share for $0.15 for a period of 2 years from closing. The warrants will contain a forced conversion provision that if the shares of the Company trade at $0.25 or more for a period of 10 trading days, the Company has the option to accelerate the expiry date to no less than 30 days from a press release advising of the same. The proceeds of $4,823,583 will be used for working capital and future acquisitions. Securities issued pursuant to this first closing are subject to trading restrictions until July 23, 2017.

The shares of Quikflo are currently halted from trading pursuant to the policies of the TSXV Exchange. Any future material acquisitions by the Company, including any acquisitions involving the proceeds of the private placement, will be subject to the approval of the Exchange.

Further Information

For further information relating to this, please contact David Lane, president or Investor Relations for the Company at +1 604 428-0511.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval in respect to the acquisition of new businesses and raising funds. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: QuikFlo Health Inc.

ReleaseID: 458065

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in PixarBio Corporation (“PixarBio” or the “Company”) (OTC PINK: PXRB) of the March 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased PixarBio securities pursuant to the Company’s private placement that closed on October 30, 2016 (the “Private Placement”); and/or publicly traded on the open market between October 31, 2016 and January 20, 2017 (the “Class Period”). The case, ALLEN v. PIXARBIO
CORPORATION f/k/a BMP HOLDINGS INC. et al, No. 2:17-cv-00496 was filed on January 25, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees; and PixarBio’s’ current and prospective development efforts lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.

Specifically, on January 23, 2017, the Securities and Exchange Commission (“SEC”) announced the temporary suspension of trading in the securities of PixarBio stating, in part, that “the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1.”

Given the SEC’s suspension of PixarBio securities, shares of PixarBio are illiquid, thus causing damage to investors.

Request more information now by clicking
here: www.faruqilaw.com/PXRB
. There is no cost or obligation to you.

Take Action

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Faruqi & Faruqi, LLP also encourages anyone with information regarding PixarBio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 458061

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ: BABY) of the March 31, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Natus stock or options between October 16, 2015 and April 3, 2016 (the “Class Period”). The case, Badger
v. Natus Medical Incorporated et al., No. 17-cv-00458 was filed on January 30, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the risk of unfulfilled payments from its contract with Venezuela’s Ministry of Health leading to a material decline in the Company’s revenues and profitability.

First, on October 16, 2015, Natus announced that its Argentinian subsidiary had entered into a three-year supply contract with the Ministry of Health of Venezuela pursuant to which the Company would receive $232.5 million, including $69 million in prepayments “expected” during the first quarter of 2016.

Then, on April 4, 2016, the Company announced lower-than-expected preliminary 2016 first quarter revenue of about $87.5 million, lower than its previous guidance of $91.5 million to $92.5 million, and below analysts’ expectations. The Company cited the previously unexpected cancellation of payments in key Venezuelan government supply contracts as a reason for the disappointing results.

Request more information now by clicking here: www.faruqilaw.com/BABY. There is no cost or obligation to you.

Take Action

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Natus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 458060

VANCOUVER, BC / ACCESSWIRE / March 23, 2017 / Fairmont Resources Inc. (TSX-V: FMR) (“Fairmont” or the “Company”) announces that, in connection with its Granitos de Badajoz (“Grabasa”) acquisition, it has elected to not proceed with a proposed financing from a European funding group due to certain discrepancies identified by the Spanish courts. As a result, Fairmont will be pursuing alternative methods of financing for the Grabasa acquisition. There is no assurance that Fairmont will be able to complete the financing required to acquire the Grabasa assets by the deadline of April 24, 2017.

About Fairmont Resources Inc.

Fairmont Resources Inc. is a rapidly growing industrial mineral and dimensional stone company trading on the Toronto Venture Exchange symbol FMR.

Fairmont’s Quebec properties cover numerous occurrences of high-grade titaniferous magnetite with vanadium, with the Buttercup property having a permit to quarry dense aggregate. Where these occurrences have been tested they have display exceptional uniformity with respect to grade. Fairmont also controls three quartz/quartzite properties, with the Forestville property having independent end user testing confirming the suitability of quartzite from Forestville for Ferro Silicon production. Fairmont is also in the process of acquiring the assets of Granitos de Badajoz (GRABASA) in Spain which includes 23 quarries and a 40,000 square metre granite finishing facility that has produced finished granite installed across Europe.

On behalf of the Board of Directors,

Michael A. Dehn
President and CEO, Fairmont Resources Inc.
Tel:647-477-2382
michael@fairmontresources.ca
www.fairmontresources.ca

For further information please contact:

Doren Quinton,
President QIS Capital
Tel:250-377-1182
info@smallcaps.ca
www.smallcaps.ca

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Fairmont cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Fairmont’s control. Such factors include, among other things: risks and uncertainties relating to Fairmont’s ability to complete the proposed private placement financing, limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Fairmont undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Fairmont Resources Inc.

ReleaseID: 458059

TORONTO, ON / ACCESSWIRE / March 23, 2017 / Fountain Asset Corp. (TSX-V: FA) (“Fountain”) announces that its investee company, The Hydropothecary Corporation (“THC”), has completed its Qualifying Transaction with BFK Capital Corp. (“BFK”), a Capital Pool Company, and is now listed on the TSX Venture Exchange. The trading symbol is “THCX”.

The Hydropothecary Corporation is licensed under the Access to Cannabis for Medical Purposes Regulations to cultivate and sell marijuana seeds and plants and dried marijuana product and to produce marijuana oils, marijuana resins and fresh marijuana products from its facilities located in Gatineau. Québec.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical marijuana licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Hydropothecary Corporation provides naturally grown and rigorously tested medical marijuana of uncompromising quality. Hydropothecary’s branding, marijuana product offering, patient service standards and product pricing are consistent with THC’s positioning as a premium brand for a legal source for medical marijuana within this new marketplace. In addition to medical marijuana production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export of medical marijuana. For further information, please contact: Sebastien St-Louis, Chief Executive Officer, at 1-866-438-THCX (8429), or email the company at invest@THCX.com.
Please visit the company’s website at www.THCX.com.

About Fountain Asset Corp.

Fountain Asset Corp. is a merchant bank which provides equity financing, bridge loan services (asset back/collateralized financing) and strategic financial consulting services to companies across many industries such as oil & gas, mining, real estate, manufacturing, retail, financial services, technology and biotechnology. For further information, please contact Jason G. Ewart at (416) 488-7760 or visit Fountain Asset Corp.’s website at www.fountainassetcorp.com.

Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Fountain Asset Corp.

ReleaseID: 458058